Gene: TATDN2

9797
-
TatD DNase domain containing 2
protein-coding
3p25.3
Ensembl:ENSG00000157014 Vega:OTTHUMG00000155361 UniprotKB:Q93075
NC_000003.12
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.177e-1 (AD)  5.344e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2241312chr3:10259616 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs11707074chr3:10250959 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PARP60.947
KIF3B0.94
CALM10.94
PIP4K2B0.937
DUSP30.936
DNAJC50.936
ARF30.935
USP70.935
LARP10.933
SAE10.933

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.672
OR4F29-0.656
MYL3-0.364
CST7-0.362
CSAG1-0.36
S100A12-0.351
MTRNR2L6-0.349
FCGR3B-0.346
CXCR2-0.345
MTRNR2L10-0.345

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in increased expression of TATDN2 mRNA28329830
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of TATDN2 mRNA19770486
D001280AtrazineAtrazine results in decreased expression of TATDN2 mRNA22378314
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of TATDN2 mRNA26377693
C006780bisphenol Abisphenol A results in increased expression of TATDN2 mRNA25047013
C006780bisphenol Abisphenol A results in increased expression of TATDN2 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of TATDN2 mRNA28628672
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of TATDN2 mRNA27339419
C018021cobaltous chloridecobaltous chloride results in increased expression of TATDN2 mRNA24386269
D019327Copper SulfateCopper Sulfate results in decreased expression of TATDN2 mRNA19549813
D003375CoumestrolCoumestrol results in increased expression of TATDN2 mRNA19167446
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of TATDN2 mRNA28628672
C000499ferric oxideferric oxide analog results in decreased expression of TATDN2 mRNA24525745
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in increased expression of TATDN2 mRNA28329830
D005485FlutamideFlutamide results in increased expression of TATDN2 mRNA24136188
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of TATDN2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of TATDN2 mRNA28628672
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of TATDN2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of TATDN2 mRNA"25554681|2562005
C051752nefazodonenefazodone results in increased expression of TATDN2 mRNA24136188
C012655nimesulidenimesulide results in increased expression of TATDN2 mRNA24136188
D010416PentachlorophenolPentachlorophenol results in increased expression of TATDN2 mRNA24642059
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of TATDN2 mRNA19162173
C006253pirinixic acidpirinixic acid results in increased expression of TATDN2 mRNA23811191
D010936Plant ExtractsPlant Extracts results in increased expression of TATDN2 mRNA23557933
C017947sodium arsenitesodium arsenite affects the expression of TATDN2 mRNA29319823
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of TATDN2 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of TATDN2 mRNA21215274
D019284ThapsigarginThapsigargin results in decreased expression of TATDN2 protein24648495
D013853ThioacetamideThioacetamide results in increased expression of TATDN2 mRNA23411599
D014241TrichloroethyleneTrichloroethylene results in increased expression of TATDN2 mRNA25549359
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of TATDN2 mRNA"26179874
D015032ZincZinc results in decreased expression of TATDN2 mRNA20932299

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0016888endodeoxyribonuclease activity, producing 5'-phosphomonoesters-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0036498IRE1-mediated unfolded protein response-TAS-  
GO:0090305nucleic acid phosphodiester bond hydrolysis-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005829cytosol-IDA-  
GO:0016607nuclear speck-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-381038XBP1(S) activates chaperone genesTAS
R-HSA-381070IRE1alpha activates chaperonesTAS
R-HSA-381119Unfolded Protein Response (UPR)TAS
R-HSA-392499Metabolism of proteinsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal